Digital therapeutics and EHRs go hand in hand: We discuss how a new AmerisourceBergen platform will make e-prescribing DTx through EHRs easier.
Robopill awaits clinical trials…and patient approval: Endiatx’s robotic pill could make medical procedures less invasive, but earning public trust may be difficult. Preempting concerns with transparency could help.
Patients still distrust Big Tech and health tech companies with their data: We unpack the implications around Big Tech health data access, Roe vs. Wade issues and healthcare literacy on the back of a new AMA survey.
Cadence enters the life science market to revolutionize drug discovery: Its OpenEye Scientific acquisition is an example of pharma’s investment in biosimulations for therapeutic research.
We detail why layoffs are only the tip of the iceberg for health tech companies like it this year.
A call for talent in revenue cycle management: We take a look at how companies are hiring for RCM and the role that RCM software adoption will play in addressing the labor shortage.
FDA approves clinical wearable that detects atrial fibrillation: We unpack what the news means for managing cardiac conditions.
PLUS: We predict where Amazon is headed next
Health systems address RPM, wearable challenges: We explore new toolkits for scaling RPM adoption, and discuss how healthcare organizations can solve the challenges in adopting the devices.
New VA report highlights EHR patient safety risks: We unpack reports of medical record hiccups, but EHR growth continues.
We unpack how Optum’s M&A streak contributed to its sky-high revenues—but economic downturn could mean higher premiums for customers.